Discover
ARQT
Arcutis Biotherapeutics, Inc.
28.26
1 x 27.71
1 x 29.00
bid
ask
+
0.73
2.65%
3 @ 04:00 PM
28.42 +0.16 (0.57%)
| Ytd | -2.69% | |
| 1y | 97.07% |
27.52
day range
28.50
13.70
52 week range
31.77
| Open | 27.53 | Prev Close | 27.53 | Low | 27.52 | High | 28.50 | Mkt Cap | 3.53B |
| Vol | 1.37M | Avg Vol | 1.80M | EPS | -0.03 | P/E | -942.00 | Forward P/E | 158.73 |
| Beta | 1.48 | Short Ratio | 7.38 | Inst. Own | 109.94% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 24.26 | 200-d Avg | 25.02 | 1yr Est | 34.63 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | 0.07 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -0.02 | -0.09 | -0.07 | -350.00% |
| 2026-02-25 | 2025-12 | 0.03 | 0.13 | 0.1 | 333.33% |
| 2025-10-28 | 2025-09 | -0.1 | 0.06 | 0.16 | 160.00% |
| 2025-08-06 | 2025-06 | -0.18 | -0.13 | 0.05 | 27.78% |
| 2025-05-06 | 2025-03 | -0.21 | -0.2 | 0.01 | 4.76% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-07 | Needham | Upgrade | Buy | Buy |
| 2026-03-02 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-02-27 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-26 | TD Cowen | Upgrade | Buy | Buy |
| 2026-02-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-26 | Needham | Upgrade | Buy | Buy |
Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-10 | BURNETT PATRICK | Officer | 120.24K | Sale |
| 2025-06-11 | CHAUDHURI BHASKAR | Director | 917.81K | Stock Award(Grant) |
| 2026-03-01 | EDWARDS LARRY TODD | Officer | 175.18K | Sale |
| 2026-06-04 | HERON PATRICK J | Director | 8.87M | Stock Award(Grant) |
| 2026-06-04 | LEONARD KEITH R JR | Director | 29.65K | Stock Award(Grant) |
| 2026-05-03 | MATSUDA MASARU | Officer | 126.69K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Suvretta Capital Management, LLC | 12.33M | 0.00 | 9.86% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 9.87M | 0.00 | 7.89% |
| 2026-03-30 | BlackRock Inc | 9.20M | 0.00 | 7.36% |
| 2026-03-30 | Rubric Capital Management LP | 8.27M | 0.00 | 6.61% |
| 2025-12-30 | Vanguard Group Inc | 7.25M | 0.00 | 5.80% |
| 2026-03-30 | State Street Corp | 6.30M | 0.00 | 5.03% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Polar Capital Biotech S Inc | 6.46M | 0.00 | 5.16% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 3.57M | 0.00 | 2.85% |
| 2026-06-29 | iShares Russell 2000 ETF | 2.95M | 0.00 | 2.36% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 2.90M | 0.00 | 2.32% |
| 2026-06-29 | American Century Small Cap Growth Inv | 1.47M | 0.00 | 1.17% |
| 2026-06-29 | American Century U.S. Small Cap Growth | 1.47M | 0.00 | 1.17% |